Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureNor Munira Hashim, Hermizi Hapidin
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Synergistic composite engineering: bridging immunomodulaftion, bone regeneration and precision therapy in osteosarcoma management
10.1016/j.nantod.2025.102952 · 2026
Modern trends of using innovative nanoparticle approaches for immune-based osteosarcoma therapy
10.1016/j.intimp.2025.115953 · 2026
Systemic strategies for osteosarcoma: advances and future directions
10.1007/s12672-025-02208-9 · 2025
UK guidelines for the management of bone sarcomas
10.1038/s41416-024-02868-4 · 2025
Risk factors for pulmonary metastases in osteosarcoma: a systematic review and meta-analysis
10.1186/s12885-026-15802-z · 2026
Prognostic nomogram for overall survival in pediatric osteosarcoma with pulmonary metastases: a SEER database analysis
2025
From bone homeostasis to skeletal metastasis and osteosarcoma: insights into osteoclast and osteoblast roles in bone remodelling and cancer
2026
Osteosarcoma and metastasis
10.3389/fonc.2021.780264 · 2021
Recurrent metastatic high-grade osteosarcoma: disease stabilization and successful pregnancy outcome following aggressive multimodality treatment
10.4103/ijmpo.ijmpo_83_17 · 2018
Advances in osteosarcoma research: pathogenesis and emerging therapeutic strategies
10.1016/j.critrevonc.2026.105252 · 2026
Osteosarcoma: current concepts and evolutions in management principles, journal of
2023
Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: a meta-analysis and clinical observation
10.1097/md.0000000000015582 · 2019
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
10.1016/s1470-2045(16)30214-5 · 2016
Completion of perioperative chemotherapy and tumor regression grade as independent predictors of one-year survival after total gastrectomy for gastric cancer: a retrospective cohort study
10.1186/s12957-026-04364-w · 2026
Pathological complete response after neoadjuvant chemotherapy in breast cancer: a literature overview
10.3390/cancers18111718 · 2026
Long-term benefit from high-dose ifosfamide in sarcoma depends on sustained prior control and timely intervention: a machine learning analysis
10.1007/s00432-025-06410-8 · 2026
High dose ifosfamide in relapsed and unresectable high-grade osteosarcoma patients: a retrospective series
10.3390/cells9112389 · 2020
Battling Chemoresistance in cancer: root causes and strategies to uproot them
10.3390/ijms22179451 · 2021
Mechanisms and advances of drug resistance in colorectal cancer: a systematic overview of multi-layered regulatory networks
10.1016/j.tranon.2026.102886 · 2026
Advancements in osteosarcoma therapy: overcoming chemotherapy resistance and exploring novel pharmacological strategies
10.3390/ph18040520 · 2025
Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance
10.1016/j.gendis.2022.11.025 · 2024
Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics
10.1016/j.gendis.2022.02.007 · 2023
Emerging therapeutic strategies for triple-negative breast cancer using ruthenium, iridium, and rhenium complexes
10.1039/d6dt01362g · 2026
Cisplatin for cancer therapy and overcoming chemoresistance
10.1016/j.heliyon.2022.e10608 · 2022
Advances in understanding cisplatin-induced toxicity: molecular mechanisms and protective strategies
10.1016/j.ejps.2024.106939 · 2024
Cisplatin resistance in oral squamous cell carcinoma: mechanisms, reversal strategies, and emerging technologies
2026
Colorectal cancer at the crossroads: the good, the bad, and the future of platinum-based drugs
10.1021/acs.chemrev.5c00041 · 2025
Doxorubicin-an agent with multiple mechanisms of anticancer activity
10.3390/cells12040659 · 2023
Different mechanisms in doxorubicin-induced cardiomyopathy: impact of BRCA1 and BRCA2 mutations
10.3390/hearts5010005 · 2024
Resistance to doxorubicin therapy in breast cancer cells could be attenuated by ligustilide: impact on autophagy and LncRNA H19
10.1186/s12906-026-05397-0 · 2026
Targeting activated pathways in doxorubicin-resistant TNBC alters signaling, survival and EMT: a double-edged sword
10.3390/ijms27062792 · 2026
Methotrexate an old drug with new tricks
10.3390/ijms20205023 · 2019
A narrative review on diagnosis and treatment of ifosfamide-induced encephalopathy, the perspective of a EURACAN reference center for sarcomas
2025
The heterogeneity and drug resistance of malignant cells and intercellular communication of microenvironment in osteosarcoma: based on single-cell analysis
10.1002/ctd2.202 · 2023
Molecular mechanisms of chemoresistance in osteosarcoma (review)
10.3892/ol.2014.1935 · 2014
NF-κB in biology and targeted therapy: new insights and translational implications
10.1038/s41392-024-01757-9 · 2024
Key signal transduction pathways and crosstalk in cancer: biological and therapeutic opportunities
10.1016/j.tranon.2022.101510 · 2022
Metabolic–immune crosstalk in osteosarcoma: mechanisms and therapeutic opportunities
2026
Tumor microenvironment in osteosarcoma: from cellular mechanism to clinical therapy
10.1016/j.gendis.2025.101569 · 2025
Targeting redox homeostasis in cancer: inhibitors of reactive oxygen species regulating cellular signalling pathways and their therapeutic implications
10.1016/j.critrevonc.2026.105204 · 2026
Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives
10.1038/s41392-024-01885-2 · doi-reference
Multiple roles of p53 in cancer development: regulation of tumor microenvironment, m6A modification and diverse cell death mechanisms
10.1016/j.jare.2024.10.026 · doi-reference
Cancer metastasis: molecular mechanisms and therapeutic interventions
10.1186/s43556-025-00261-y · doi-reference
Advancements in 3D cell culture Systems for Personalizing Anti-Cancer Therapies
10.3389/fonc.2021.782766 · doi-reference
3D cell culture models: drug pharmacokinetics, safety assessment, and regulatory consideration
10.1111/cts.13066 · doi-reference
Nanomaterials for delivery of medicinal plant extracts and phytochemicals: potential applications and future perspectives
10.1016/j.plana.2025.100161 · doi-reference
Nanocarrier-assisted phytochemical drug delivery in cancer therapy: a bibliometric analysis and integrative review of challenges, innovations, and translational potential
10.1016/j.prerep.2026.100075 · doi-reference
Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics
10.1186/s12951-023-01826-1 · doi-reference
Recent advances in drug delivery systems for osteosarcoma therapy and bone regeneration
10.1038/s43246-024-00612-2 · doi-reference
Nanotechnology-enabled delivery systems to improve the bioavailability and efficacy of polyphenolic compounds
10.1016/j.prenap.2026.100532 · doi-reference
Evaluation of tumor control and Normal tissue complication probabilities in patients receiving comprehensive nodal irradiation for left-sided breast Cancer
10.3390/curroncol31060241 · doi-reference
Role of tumor microenvironment in cancer progression and therapeutic strategy
10.1002/cam4.5698 · doi-reference
Therapeutic resistance and combination therapy for cancer: recent developments and future directions
10.1038/s41598-025-12725-w · doi-reference
Phytochemicals in Cancer therapy: a structured review of mechanisms, challenges, and Progress in personalized treatment
10.1002/cbdv.202402479 · doi-reference
Phytochemicals that interfere with drug metabolism and transport, modifying plasma concentration in humans and animals
10.1177/15593258221120485 · doi-reference
Curcumin as a modulator of drug metabolism and gene expression: implications for pharmacogenomics
10.1016/j.prerep.2025.100067 · doi-reference
Exploring synergistic effects of bioactive compounds and pharmaceuticals in therapeutic applications
10.1016/j.jhip.2026.02.009 · doi-reference
Estimating drug concentration–response relationships by applying causal inference methods for continuous point exposures and time-to-event outcomes
10.1177/09622802231212274 · doi-reference
Selection of clinically relevant drug concentrations for in vitro studies of candidates drugs for cancer repurposing: a proposal
10.1007/s12094-023-03352-w · doi-reference
Far from being a simple question: the complexity between in vitro and in vivo responses from nutrients and bioactive compounds with antioxidant potential
10.1016/j.foodchem.2022.134351 · doi-reference
Exploring the therapeutic potential of phytochemicals: challenges and strategies for clinical translation
10.1016/j.phymed.2025.157090 · doi-reference
Bioaccessibility and bioavailability of phytochemicals: influencing factors, improvements, and evaluations
10.1016/j.foodhyd.2022.108165 · doi-reference
SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets
10.1016/j.gpb.2022.01.004 · doi-reference
Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls
10.1016/j.drudis.2019.09.002 · doi-reference
Evaluation of synergism in drug combinations and reference models for future orientations in oncology
10.1016/j.crphar.2022.100110 · doi-reference
DNA damage response and repair in osteosarcoma: defects, regulation and therapeutic implications
10.1016/j.dnarep.2021.103105 · doi-reference
A natural protopanaxatriol from Panax notoginseng enhances osteosarcoma sensitivity to ferroptosis via ASCL4 upregulation
10.1016/j.jff.2024.106488 · doi-reference
R. Skouta, Eleina M. Zaitsev, Caroline E. Gleason, Darpan N. Patel, Andras J. Bauer, Alexandra M. Cantley, Wan S. Yang, B. Morrison, Brent R. Stockwell, Ferroptosis: An Iron-dependent form of nonapoptotic cell death
10.1016/j.cell.2012.03.042 · doi-reference
Interaction mechanisms between autophagy and ferroptosis: potential role in colorectal cancer
10.4251/wjgo.v15.i7.1135 · doi-reference
The cell biology of ferroptosis
10.1038/s41580-024-00703-5 · doi-reference
Brief guide to detecting ferroptosis
10.1016/j.mocell.2025.100276 · doi-reference
Ferroptosis: a cell death connecting oxidative stress, inflammation and cardiovascular diseases
10.1038/s41420-021-00579-w · doi-reference
Ferroptosis: mechanisms, biology and role in disease
10.1038/s41580-020-00324-8 · doi-reference
Ferroptosis: emerging mechanisms, biological function, and therapeutic potential in cancer and inflammation
10.1038/s41420-024-01825-7 · doi-reference
Ferroptosis, a distinct form of cell death, and research progress on its modulators
10.3390/ph18121785 · doi-reference
Curculigoside exhibits multiple therapeutic ef fi cacy to induce apoptosis and ferroptosis in osteosarcoma via modulation of ROS and tumor microenvironment
10.1016/j.tice.2025.102745 · doi-reference
Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery
10.1186/s13046-024-02949-5 · doi-reference
Physiological and tumor-associated angiogenesis: key factors and therapy targeting VEGF/VEGFR pathway
10.1016/j.biopha.2024.117585 · doi-reference
Cyclovirobuxine D inhibits the growth of osteosarcoma cells through the induction of autophagy flux arrest by promoting lysosomal acidification
10.1016/j.jff.2024.106210 · doi-reference
Rhizoma Paridis saponins suppresses vasculogenic mimicry formation and metastasis in osteosarcoma through regulating miR-520d-3p/MIG-7 axis
10.1016/j.jphs.2022.08.005 · doi-reference